Reference : The genetic architecture of mitochondrial dysfunction in Parkinson's Disease
Scientific journals : Article
Human health sciences : Neurology
http://hdl.handle.net/10993/34325
The genetic architecture of mitochondrial dysfunction in Parkinson's Disease
English
Krüger, Rejko mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Larsen, Simone mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Hanss, Zoé mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
Jan-2018
Cell and Tissue Research
Springer
Yes
International
[en] mitochondrial ; dysfunction ; parkinson's
[en] Mitochondrial impairment is a well-established pathological pathway implicated in Parkinson’s disease (PD). Defects of the complex I of the mitochondrial respiratory chain have been found in post mortem brains from sporadic PD patients. Furthermore, several disease-related genes are linked to mitochondrial pathways, such as PRKN, PINK1, DJ-1 and HTRA2 and are associated to mitochondrial impairment. This phenotype can be caused by the dysfunction of mitochondrial quality control machinery at different levels: molecular, organellar or cellular. Mitochondrial unfolded protein response represents the molecular level and implicates various chaperones and proteases. If the molecular level of quality control is not sufficient, the organellar level is required and involves mitophagy and mitochondrial derived vesicles to sequester whole dysfunctional organelle or parts of it. Only when the impairment is too severe, it leads to cell death via apoptosis which defines the cellular level of quality control. Here we review how currently known PD-linked genetic variants interfere with the different levels of mitochondrial quality control. We discuss the graded risk concept of the most recently identified PARK loci (PARK 17-23) and some susceptibility variants such as GBA, LRRK2 and SNCA. Finally, the emerging concept of rare genetic variants as candidates for PD, such as HSPA9, TRAP1 and RHOT1 complete the picture of the complex genetic architecture of PD that will direct future precision medicine approaches.
Luxembourg Centre for Systems Biomedicine (LCSB)
Fonds National de la Recherche - FnR
Researchers ; Professionals ; Students
http://hdl.handle.net/10993/34325
FnR ; FNR6682797 > Rejko Krueger > > Comprehensive Assessment Of Endophenotypes In Neurodegenerative Diseases - Translating Impaired Molecular Signalling Pathways Into Novel Therapeutic Strategies For Parkinson’S Disease > 01/06/2014 > 31/05/2019 > 2013

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Larsen_et_al-2018-Cell_and_Tissue_Research.pdfPublisher postprint1.81 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.